ישראל - עברית - Ministry of Health

cts ltd - metyrapone - קפסולות - metyrapone 250 mg - metyrapone - metyrapone - diagnostic test of secondary adrenocortical insufficiency, treatment of resistant edema associated with increased aldosterone secretion.

ישראל - עברית - Ministry of Health

truemed ltd, israel - opicapone - קפסולה קשיחה - opicapone 50 mg - opicapone

ישראל - עברית - Ministry of Health

cts ltd - metyrapone 250 mg - capsules - metyrapone - diagnostic test of secondary adrenocortical insufficiency, treatment of resistant edema associated with increased aldosterone secretion.

ישראל - עברית - Ministry of Health

תרופארם שיווק 1985 בע"מ - רופא

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 3 miu / 0.5 ml - solution for injection - interferon alfa-2a - condylumata acuminata. hepatitis b,c. hairy cell leukemia. cml. aids related kaposis sarcoma. renal cell carcinoma.follicular non-hodgkin's lymphoma. patients with ajcc stage ii malignant melanoma (breslow tumour thickness > 1.5 mm, no lymph node involvement or cutaneous spread) who are free of disease after surgery.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 4.5 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 6 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 9 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - interferon alfa 2b 18 miu/ml - solution for injection - interferon alfa-2b - chronic hepatitis b, chronic hepatitis c, hairy cell leukemia, chronic myelogenous leukemia, aids related kaposi`s sarcoma, malignant melanoma.treatment of metastatic or recurrent renal cell carcinoma non hodgkin`s lymphoma. treatment of high tumour burden follicular lymphoma as adjunct to apropriate combination induction chemotherapy such as a chop like regimen.

ישראל - עברית - Ministry of Health

"אפוס טכנולוגיות רפואה וספורט בע""מ" - כלל האוכלוסיה - ערכת אפוס לאימון ושיקום יציבות ושליטה עצבית-שרירית